LUCIA MORENO: Open Payments
NPI 1720435878 · KANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$752 in 41 payments from 15 companies in 2025. Trend: 2023 $674 · 2024 $890 · 2025 $752
Food & beverage: $752
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 9 | $170 |
| Novartis Pharmaceuticals Corporation | 5 | $90 |
| Lundbeck LLC | 4 | $71 |
| ABBVIE INC. | 3 | $57 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Viatris Specialty LLC | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Novo Nordisk Inc | 2 | $38 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
Products named: MOUNJARO, LEQVIO, REXULTI, QULIPTA, YUPELRI, CAPLYTA, GEMTESA, ZEPBOUND.
Industry payments across KS — which companies pay providers there.
